{
"id":"mk19_b_pm_q006",
"number":6,
"bookId":"pm",
"correctAnswer":"A",
"title":"Question 6",
"stimulus":[
{
"type":"p",
"hlId":"0e12d6",
"children":[
"A 36-year-old woman is evaluated for a change in her asthma status. She has spirometry-confirmed asthma; she has never required hospitalization. She is a nonsmoker and has allergic rhinitis. Her only medication is an albuterol metered-dose inhaler as needed. She now requires albuterol use three times weekly but never more than once per day. She demonstrates good inhaler technique."
]
},
{
"type":"p",
"hlId":"3654c3",
"children":[
"On physical examination, vital signs are normal. ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"Oxygen saturation"
]
},
" is 98% with the patient breathing ambient air. BMI is 24. She is not currently wheezing. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"b34a3f",
"children":[
"Spirometry today is normal."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Beclomethasone dipropionate with albuterol"
}
},
{
"letter":"B",
"text":{
"__html":"Methacholine challenge testing"
}
},
{
"letter":"C",
"text":{
"__html":"Montelukast at bedtime"
}
},
{
"letter":"D",
"text":{
"__html":"No additional management"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"c26e8c",
"children":[
"Guidelines recommend that patients with mild persistent asthma use inhaled glucocorticoids whenever an inhaled short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist is used to reduce the risk of serious exacerbations and to control symptoms."
]
},
{
"type":"keypoint",
"hlId":"03551a",
"children":[
"Clinicians should review correct inhaler use with patients who have airways disease at each visit."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"6c59b4",
"children":[
"The most appropriate management for this patient is to add beclomethasone dipropionate with albuterol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") during asthma symptoms. The patient has persistent asthma defined by use of her short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist (albuterol) more than two times weekly but not more than once per day. She has no comorbidities or risk factors for severe exacerbation. Based on studies demonstrating that as-needed use of inhaled glucocorticoids in combination with airway dilators is noninferior to daily use of glucocorticoids and superior to short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonists alone, the 2020 Global Initiative for Asthma guidelines recommend that patients with mild persistent asthma use an inhaled glucocorticoid whenever they use an inhaled short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist to reduce the risk of serious exacerbations and to control symptoms. An alternative is the inhaler combination of low-dose glucocorticoid-formoterol taken as needed for symptom relief. The National Asthma Education and Prevention Program also recommends an inhaled glucocorticoid, either as a daily low-dose inhaled glucocorticoid plus as-needed short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist or as-needed concomitant inhaled glucocorticoid and short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist. In addition to assessing symptom control, modifiable risk factors, and comorbidities, clinicians should review correct inhaler use with patients at each visit."
]
},
{
"type":"p",
"hlId":"64e035",
"children":[
"Bronchial challenge testing with methacholine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is used to identify bronchial hyperresponsiveness, a diagnostic feature of asthma. This is particularly helpful in patients whose symptoms are suggestive of asthma but for whom other pulmonary function test results are normal. A negative response to bronchial challenge can exclude asthma; however, a positive test can be caused by other conditions. Performing methacholine challenge testing is not appropriate because the patient's diagnosis of asthma has already been established with spirometry."
]
},
{
"type":"p",
"hlId":"e895c5",
"children":[
"Montelukast (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is an oral leukotriene-receptor antagonist that has a modest bronchodilation effect and can also treat upper airway conditions such as allergic rhinitis. Patients with aspirin-exacerbated respiratory disease often respond well to montelukast. Adding montelukast is not appropriate because the use of a daily medication is not recommended for intermittent asthma symptoms."
]
},
{
"type":"p",
"hlId":"fa1dfb",
"children":[
"Not changing this patient's management (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is not appropriate because the use of short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonists without an inhaled glucocorticoid does not reduce exacerbation risk."
]
}
],
"relatedSection":"mk19_b_pm_s2_1_6_1",
"objective":{
"__html":"Treat mild persistent asthma with combination airway dilator and inhaled glucocorticoid."
},
"references":[
[
"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Available from: ginasthma.org/wp-content/uploads/2021/04/GINA-2021-Main-Report_FINAL_21_04_28-WMS.pdf. Accessed May 5, 2021."
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":55,
"B":6,
"C":16,
"D":23,
"E":0
},
"hlIds":[
"0e12d6",
"3654c3",
"b34a3f",
"cb2b54",
"c26e8c",
"03551a",
"6c59b4",
"64e035",
"e895c5",
"fa1dfb"
]
}